Antifibrotic

Questions discussed in this category

Do you consider administration of nintedanib or pirfenidone via enteral tube in patients unable to take PO due to recurrent aspiration?

1 Answer available

Do you ever consider close clinical monitoring over antifibrotic therapy in patients ascribed an MDD diagnosis of IPF who have normal lung function and are asymptomatic?

2 Answers available

Is there an age at which you consider not starting antifibrotic therapy in a patient with IPF?

1 Answer available

Would you consider the use of dual antifibrotic therapy (nintedanib and pirfenidone together) for progressive fibrosing ILD?

4 Answers available

Does your approach to treating latent tuberculosis differ in a patient on anti-fibrotic therapy?

1 Answer available

When do you begin antifibrotic therapy for a patient with newly diagnosed ILD that is not IPF?

Do you base the decision on FEV1, 6MWD or symptoms at initial evaluation, or progression over time?

6 Answers available

Do you prescribe antifibrotics to patients with combined pulmonary fibrosis and emphysema (CPFE)?

1 Answer available

Is there a role for antifibrotic therapy in post COVID-19 pulmonary fibrosis?

1 Answer available

Papers discussed in this category

Eur Respir Rev, 2021 Dec 15

Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection.

Ann Am Thorac Soc,

Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment.

Am J Respir Crit Care Med,

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.

The European respiratory journal, 2018-08

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.

N Engl J Med, 2019 Sep 29

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

Arthritis & rheumatology (Hoboken, N.J.), 2017-03

Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease.

N. Engl. J. Med., 2019 May 20

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

Lancet Respir Med, 2021 Jan

Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.

Eur Respir J, 2019 Apr 18

Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials.

Ann Am Thorac Soc, 2017 May

Minimizing Tuberculosis Risk in Patients Receiving Anti-TNF Therapy.

American journal of respiratory and critical care medicine, 2019 Jul 15

Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis.

PloS one, 2022 Feb 03

Tolerability of nintedanib in the elderly with idiopathic pulmonary fibrosis: A single-center retrospective study.

Respiration; international review of thoracic diseases, 2022 Nov 10

Observational, Multicenter Study on the Efficacy, Tolerability, and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis Older than 80 Years.

Lancet (London, England), 2011-05-21

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.

The New England journal of medicine, 2018 Aug 26

Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.

Respiratory research, 2021 Apr 26

Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities.

The New England journal of medicine, 2014 May 18

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Respiratory investigation, 2020 Sep 03

Tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis.

Advances in therapy, 2023 Mar 16

A Narrative Review of Real-World Data on the Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.

American journal of respiratory and critical care medicine, 2011-10-01

Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study.

Chest, 2011-07

Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium.

American journal of respiratory and critical care medicine, 2023 Jan 01

Antifibrotics and Reduced Mortality in Idiopathic Pulmonary Fibrosis: Immortal Time Bias.

Antifibrotic

Questions discussed in this category

Papers discussed in this category

Related Topics